JACQUELINE CASTLE: Open Payments
NPI 1255040663 · CONYERS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 46 payments from 19 companies in 2025. Trend: 2023 $444 · 2024 $586 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Dexcom, Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $85 |
| Lilly USA, LLC | 4 | $81 |
| Amgen Inc. | 4 | $64 |
| Novo Nordisk Inc | 4 | $60 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Esperion Therapeutics, Inc. | 2 | $51 |
| SANOFI-AVENTIS U.S. LLC | 2 | $39 |
Products named: REXULTI, Dexcom G6 Transmitter, CAPLYTA, BREZTRI, SHINGRIX, NEXLETOL, FARXIGA, OTEZLA.
Industry payments across GA — which companies pay providers there.
